根据协议条款，和铂医药将与百时美施贵宝合作推进及加速多特异性抗体发现项目。为此，和铂医药将 获得总计9000万美元的付款，若百时美施贵宝选择推进所有潜在项目，和铂医药还可获得高达10.35亿 美元的开发及商业里程碑付款，以及基于未来产品净销售额的分级特许权使用费。 12月17日，和铂医药发布公告称，公司与百时美施贵宝达成长期全球战略合作及许可协议，双方将共同 研发新一代多特异性抗体疗法。 ...

和铂医药-B(02142)小幅高开后走低，一度跌超5%，现跌幅收窄。截至发稿，跌2.08%，报12.72港元， 成交额3645.09万港元。 消息面上，和铂医药今早宣布，与百时美施贵宝达成长期全球战略合作及许可协议，双方将共同研发新 一代多特异性抗体疗法。根据协议条款，和铂医药将与百时美施贵宝合作推进及加速多特异性抗体发现 项目。和铂医药将获得总计9000万美元的付款，若百时美施贵宝选择推进所有潜在项目，和铂医药还可 获得高达10.35亿美元的开发及商业里程碑付款，以及基于未来产品净销售额的分级特许权使用费。 ...

消息面上，和铂医药今早宣布，与百时美施贵宝达成长期全球战略合作及许可协议，双方将共同研发新 一代多特异性抗体疗法。根据协议条款，和铂医药将与百时美施贵宝合作推进及加速多特异性抗体发现 项目。和铂医药将获得总计9000万美元的付款，若百时美施贵宝选择推进所有潜在项目，和铂医药还可 获得高达10.35亿美元的开发及商业里程碑付款，以及基于未来产品净销售额的分级特许权使用费。 智通财经APP获悉，和铂医药-B(02142)小幅高开后走低，一度跌超5%，现跌幅收窄。截至发稿，跌 2.08%，报12.72港元，成交额3645.09万港元。 ...

又一家跨国药企向和铂医药抛来橄榄枝！ 12月17日，和铂医药(股票代码：02142.HK)宣布与百时美施贵宝达成长期全球战略合作及许可协议，双 方将共同研发新一代多特异性抗体疗法。 和铂医药有望获得逾11亿美元付款 根据协议条款，和铂医药将与百时美施贵宝合作推进及加速多特异性抗体发现项目。为此，和铂医药将 获得总计9000万美元的付款，若百时美施贵宝选择推进所有潜在项目，和铂医药还可获得高达10.35亿 美元的开发及商业里程碑付款，以及基于未来产品净销售额的分级特许权使用费。 百时美施贵宝是全球领先制药企业，也是首批进入中国的跨国制药企业，专注于肿瘤学、血液学、免疫 与纤维化及心血管疾病等领域的药物研发。近年来，该公司依托全球研发与商业化能力，持续推动创新 药从实验室走向临床应用，实现药物的临床价值及商业价值。 以Harbour Mice等核心技术平台为依托，和铂医药快速推动"抗体+"技术转化，已研发出20余款具有差 异化竞争优势的创新产品。其中，核心产品HBM9161于2021年获得国家药监局授予的"突破性治疗认 证"，并已递交上市申请。此外，其他多条差异化产品管线也在稳步推进中。 在人工智能赋能生物医药创 ...

Core Insights - The establishment of the Heptagon Pharmaceuticals-AstraZeneca Innovation Laboratory in Beijing marks a significant milestone in the collaboration between the two companies, enhancing their strategic partnership in drug development [1][2] - Heptagon Pharmaceuticals has formed partnerships with multiple multinational pharmaceutical companies, accumulating over $10 billion in total collaboration agreements [1] - The collaboration aims to develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions, with a focus on integrating AI in drug design and clinical development [2] Company Developments - Heptagon Pharmaceuticals has expanded its self-developed pipeline from 5 products to over 20, covering various therapeutic areas including oncology, inflammation, immune diseases, metabolic diseases, and central nervous system disorders [2] - The newly unveiled innovation laboratory is equipped with a comprehensive antibody drug innovation development platform and an AI wet-dry laboratory platform, which are set to accelerate the research and development process [1] Strategic Collaborations - The partnership includes a diversified collaboration model comprising research cooperation, equity investment, and the establishment of the Beijing Innovation Center, which injects new momentum into innovative drug development [1] - The collaboration with AstraZeneca is seen as a breakthrough in traditional Sino-foreign pharmaceutical partnerships, potentially leading to more innovative outcomes [2]

Core Viewpoint - Heptares Therapeutics-B (02142) saw a stock increase of over 6%, reaching HKD 13.23 with a trading volume of HKD 9.9394 million, following the announcement of the establishment of the AstraZeneca Innovation Lab in Beijing, indicating a deepening collaboration between the two companies [1][1][1] Group 1: Collaboration and Development - The official unveiling of the AstraZeneca Innovation Lab on October 25 marks a significant step in the partnership between Heptares Therapeutics and AstraZeneca, enhancing the full-process research and development of next-generation antibody drugs [1][1] - The collaboration has evolved into a diversified model that includes research cooperation, equity investment, and the establishment of an innovation center in Beijing, injecting new momentum into innovative drug development [1][1][1] Group 2: Research Focus - In March, Heptares Therapeutics and AstraZeneca entered into a global strategic partnership to jointly develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions [1][1] - The newly established innovation lab is equipped with Heptares Therapeutics' antibody drug innovation development platform and an AI wet-dry lab platform, which are set to be officially put into use, facilitating the research and development of new therapeutic antibodies across multiple fields [1][1][1]

Core Viewpoint - The collaboration between Heptagon Pharmaceuticals and AstraZeneca has deepened with the establishment of an innovative laboratory in Beijing, enhancing the development of next-generation antibody drugs [1] Group 1: Company Developments - Heptagon Pharmaceuticals-B (02142) saw a stock increase of over 6%, reaching HKD 13.23 with a trading volume of HKD 9.94 million [1] - The newly unveiled AstraZeneca Innovation Laboratory in Beijing marks a significant step in the partnership, facilitating a comprehensive R&D process for antibody drugs [1] - The collaboration has evolved into a diversified model that includes R&D cooperation, equity investment, and the establishment of an innovation center in Beijing [1] Group 2: Research and Development - In March, Heptagon Pharmaceuticals and AstraZeneca entered a global strategic partnership to develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions [1] - The innovation laboratory is fully prepared and will soon commence operations, integrating Heptagon's antibody drug innovation platform with AI wet and dry lab capabilities [1] - This initiative aims to accelerate the development of therapeutic antibodies across multiple fields [1]

Core Insights - The establishment of the Harbour Mice-AstraZeneca Innovation Laboratory in Beijing marks a significant milestone in the collaboration between Harbour Mice and AstraZeneca, creating a diversified cooperation model that includes R&D collaboration, equity investment, and the establishment of an innovation center [1][3][5] Group 1: Collaboration and Innovation - The partnership aims to develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions, leveraging advanced technologies and resources [3][5] - The newly unveiled innovation laboratory integrates Harbour Mice's fully human antibody technology with AstraZeneca's expertise in disease biology, clinical development, and AI drug design, serving as a strategic hub for innovation [5][6] - The collaboration has evolved from a single licensing agreement to a comprehensive ecosystem-building approach, enhancing trust and cooperation between the two companies [7] Group 2: Technological Advancements - Harbour Mice's antibody technology platform, including the Harbour Mice and HCAb PLUS™ systems, addresses traditional challenges in antibody development, enabling the creation of fully human antibodies and expanding applications to bispecific antibodies, ADCs, CAR-T, RNA therapies, and AI [6][7] - The integration of AI and big data into the antibody development process is expected to significantly accelerate the research and development of new therapeutic antibodies [7][8] Group 3: Future Outlook - Harbour Mice plans to expand its pipeline from 5 to over 20 products, covering various therapeutic areas such as oncology, inflammation, metabolic diseases, and central nervous system disorders [8] - The company aims to strengthen its innovation capabilities and deepen platform empowerment, positioning itself as a key player in the global pharmaceutical innovation chain [8]